



Carlos Alvarez, Mayor

Office of Grants Coordination
Ryan White Program
111 NW 1st Street, 19th Floor
Miami, Florida 33128
T 305-375-4742 F 305-375-4454

miamidade.gov

September 23, 2010

SENT VIA ELECTRONIC MAIL

Dear Ryan White Part A and/or MAI-funded Service Provider:

Enclosed for your information and distribution is a revised Ryan White Program Prescription Drug Formulary sorted in the order of drug classification, brand name, generic name and HRSA d-code and the comments/notations page, dated 9/13/2010. This new version is being sent in electronic PDF format in all four (4) sorts to facilitate its use and dissemination to all interested parties. Please note that this new version will also be available on the Office of Grants Coordination's Ryan White Program website (www.miamidade.gov/RyanWhite/).

Effective September 13, 2010, at the recommendation of the Miami-Dade HIV/AIDS Partnership, the following changes were made to the Formulary:

- Hydrocodone/Acetaminophen 5/500mg (generic only) has been added as a cost saving measure to prevent costly complications for anorectal surgery patients (clients) and to restrict the drug to anorectal surgery patients (clients). Although only the generic form is covered by the Ryan White Program, this medication is also known as Hydrocodone/APAP 5/500mg, Vicodin, or Lortab. The HRSA d-code is d03428.
- Restrict Hydrocodone/Acetaminophen 5/500mg (generic only) to a maximum utilization of a 30-day supply [for anorectal surgery patients (clients)].

In addition, the following medications have been removed from the Formulary, because they are no longer available on the market:

- Maxaquin (lomefloxacin) – d00104 (antimicrobial)
- Ultrase (pancrelipase) – d01002 (wasting/weight loss medication)

The Ryan White Program Prescription Drug Formulary is revised periodically by the Miami-Dade HIV/AIDS Partnership. It is imperative that all revisions to the Formulary be carefully reviewed and understood by direct service staff and recipients of the Ryan White Part A and Minority AIDS Initiative (MAI)-funded medications. Please notify program staff and clients immediately of this revision as appropriate.

If further clarification is needed on these changes to the Formulary, please contact Vigermina Vega, Contracts Officer, or Carla Valle-Schwenk, Program Administrator, at (305) 375-4742.

Sincerely,


Theresa Fiano
Assistant Director

Enclosure

- c: Vigermina Vega, Contracts Officer, OGC
Carla Valle-Schwenk, Program Administrator, OGC
Clarisol Nilsen, Fiscal Officer, OGC
Andrae Corrigan, President, ACMS, Inc. (local office)
Beth Hayden, Senior Administrator, Behavioral Science Research Corporation

